血清mTOR检测对消化系统恶性肿瘤患者的临床意义  

作　　者：韩丽红[1] 闫斌[2] 秦艳晶[1] 白晓荃[1] 于跃利[2] 

机构地区：[1]包头医学院生物化学教研室,内蒙古包头014040 [2]包头医学院第一附属医院,内蒙古包头014010

出　　处：《中国医学装备》2014年第B08期11-11,共1页China Medical Equipment

摘　　要：目的:探讨消化系统恶性肿瘤患者血清哺乳动物雷帕霉素靶蛋白(m TOR)水平的变化及其与消化系统恶性肿瘤发生、发展的关系。方法:采用酶联免疫吸附(ELISA)方法测定100例消化系统恶性肿瘤患者及100例健康体检者血清中m TOR的含量。结果:血清m TOR在消化系统恶性肿瘤患者含量显著高于健康体检者(P<0.01)。结论:血清m TOR检测对消化系统恶性肿瘤诊断及判断预后有意义。Objective： To investigate the change of mammalian target of rapamycin （mTOR） in serum of the patients with malignant tumor of digestive system and the correlation with the initiation and development of malignant tumor of digestive system. Methods： The content of mTOR in serum is measured by enzyme-linked immunosorbent assay （ELISA） in 100 patients with malignant tumor of digestive system and 100 healthy subjects. Results： The content of mTOR in serum in patients with malignant tumor of digestive system were significantly higher than healthy subjects （P 〈0.01 ）. Conclusion： The detection of mTOR in serum is of great significance to the diagnosis and prognosis of malignant tumor of digestive system.

关 键 词：消化系统恶性肿瘤 哺乳动物雷帕霉素靶蛋白 酶联免疫吸附 

分 类 号：R735[医药卫生—肿瘤]